Thanks again BDAZ for your incredible and valuable insight. And thanks BKC for expressing the potential so effectively.

I avoided listening to Don's Mar 4th update because I was upset with Zenith. However, curiousity got the better of me so I have just downloaded the webcast and listened to it 3 times and I need to get the thoughts out of my head. I've read comments from others and generally didn't get a very positive impression from them.

However, after listening to the webcast 3 times I feel much more positive about the future of RVX and Zenith and much of that is due to what BKC said - "it's the science" as well as BDAZ's perspectives re RVX's BET inhibition approach. I would urge investors to listen to the webcast a few times and print it and study it in detail.

So here are my rambling stream of consciousness thoughts (hope readers don't mind).

1. In terms of Don's presentation it seemed pretty normal to me except he wasn't using his "we're pretty excited about this" statement on every page. I imagine he took some heat about Zenith. He presented very complex (but valuable) information for everyone but scientists to understand.
2. Dr Sweeny's presentation was excellent...clear and helpful. Dr Sweeny strikes me as a highly talented, highly credible and knowledgeable scientist.
3. One of the things that struck me about Dr Sweeny's presentation of the BETonMACE trial is that the trial, in and of itself, is a major asset for RVX. Think of the value this adds to the company. If I was someone looking to buy Resverlogix I would consider this trial as a significant asset! Rather than thinking of the trial as a long drawn out affair with costs, etc it is in fact an asset with approvals in place, dosing started, scientists, clinics, the trial managers, drug production, a highly respected steering committee all in place and all fully aware of this company and it's achievements. So congratulations to Don and the scientists for designing and implementing an approved EU trial in such a short time.
4. The trial has been implemented ahead of plan.
5. The trial designers received excellent feedback from scientists in the UK, Germany and Sweden.
6. This trial will be collecting data for apabetalone's impact on Alzheimer's within a subset of an estimated 800 patients.
7. There will be a subset of patients with chronic kidney disease for analysis so they are making progress on this front in addition to the CKD trial if I understood it correctly. It seems like there is a strong link between ALP(serum alkaline phosphatase) and CKD and the evidence suggests apabetalone has a positive role here.
8. The futility analysis will be done after 125 events (non fatal MI, death, stroke). So if there is no postive effect or if there are safety issues the trial will be discontinued. But if it continues it does sort of imply a very positive potential indication.
9. Animal data are being submitted to the FDA and may result in some trials being conducted in the USA.
10. The trial will be conducted in between 11 and 13 countries (and 177 clinics) and now includes Taiwan! However, I did not see China in Don's charts. This seems odd given that Hepalink is based there and the growth of CVD/diebetes melletis is 15% annually.
11. From what I understand with the scientists involved the trial provides a network to help RVX stay aware of other scientific developments and competitive intellegence.
12. On slide 7 Don presents a revised business model that could expedite revenue timelines and also indicated new compounds have been tested on animals.
13. There continues to be more rapid scientific discovery on the MOA of apabetalone (rvx-208) and as these discoveries continue and are absorbed by the scientific communities, BP and other investors momentum will build in interest toward both Resverlogix, Zenith and specific compounds they build.
14. A phase 2 PNH trial is in consideration.
15. It seems that the breadth of impact of apabetalone (rvx-208) is very wide and includes many inflammatory conditions.
16. So from my perspective the RVX and Zenith scientists have a very interesting and busy schedule for this next year and beyond. Victories for these people will truly be rewarding and well deserved.
17. Resverlogix is continuing to get the message out to the scientific and investment communities. They have made huge accomplishments for a tiny company but quite often these days the little known gems that explode with huge ideas that the "big guys" never see until it happened. We see it happen continuously in many businesses.
18. I guess it is very obvious and probably doesn't need stating but perhaps the biggest assets these companies have are their specific knowledge of the BET inhibitors they have chosen, their scaffolds and processes. They own this and have 8 years of expertise over any other company...no one seems close. They also have many patents and these continue to grow.

Finally, on slide 21 of Don's presentation - 2016 - Milestone check list - Point 2 states - Announce a second licensing/partnering development deal.

• So I listened to what Don said for a 4th time and what he said was "We will announce a second licensing/partnering development deal in 2016".

So let's not forget that. Don made a very specific and firm statement. I will not forget it!!!!!

I remain long on the stock and currently it is an excellent buying time. Many triggers could drive this stock way up, particularly a new regional deal.

I feel there is incredible science happening here and it is so innovative that BP won't understand it until Don's chess game plays out and "whacks them upside the head".

So GLTA.

Cheers

Toinv